1. Home
  2. ASG vs NERV Comparison

ASG vs NERV Comparison

Compare ASG & NERV Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

ASG

Liberty All-Star Growth Fund Inc.

HOLD

Current Price

$5.23

Market Cap

328.8M

Sector

Finance

ML Signal

HOLD

Logo Minerva Neurosciences Inc

NERV

Minerva Neurosciences Inc

HOLD

Current Price

$6.60

Market Cap

301.6M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
ASG
NERV
Founded
N/A
2007
Country
United States
United States
Employees
N/A
N/A
Industry
Investment Managers
Biotechnology: Pharmaceutical Preparations
Sector
Finance
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
328.8M
301.6M
IPO Year
1995
2014

Fundamental Metrics

Financial Performance
Metric
ASG
NERV
Price
$5.23
$6.60
Analyst Decision
Buy
Analyst Count
0
2
Target Price
N/A
$10.50
AVG Volume (30 Days)
270.1K
202.6K
Earning Date
01-01-0001
05-12-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
$41,175,600.00
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$4.55
$1.30
52 Week High
$5.69
$12.46

Technical Indicators

Market Signals
Indicator
ASG
NERV
Relative Strength Index (RSI) 59.85 52.92
Support Level $5.04 $5.69
Resistance Level $5.27 $6.69
Average True Range (ATR) 0.07 0.56
MACD 0.02 0.13
Stochastic Oscillator 93.29 59.59

Price Performance

Historical Comparison
ASG
NERV

About ASG Liberty All-Star Growth Fund Inc.

Liberty All Star Growth Fund Inc is the United States based diversified, closed-end management investment company. Its investment objective is to seek long-term capital appreciation through investment in a diversified portfolio of equity securities. The company's portfolio of investments consists of different industries such as consumer discretionary, consumer staples, healthcare, industrial, information technology and others.

About NERV Minerva Neurosciences Inc

Minerva Neurosciences Inc a clinical-stage biopharmaceutical company focused on the development and commercialization of certain proprietary product candidates to treat patients suffering from central nervous system (CNS) diseases. Its product candidate, Roluperidone, is in development for the treatment of negative symptoms in patients diagnosed with schizophrenia. Its Clinical-Stage Programs include Roluperidone and Seltorexant. The company's operations are organized into one operating and reportable segment focused on the development and commercialization of proprietary product candidates to treat patients suffering from CNS diseases.

Share on Social Networks: